IONIS PHARMACEUTICALS INCIONSEarnings & Financial Report

Nasdaq · pharmaceutical industry

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

NextMar 13, 2026

Revenue

$156.7M

Gross Profit

$154.4M

Operating Profit

$-160.2M

Net Profit

$-128.6M

Gross Margin

98.5%

Operating Margin

-102.2%

Net Margin

-82.1%

YoY Growth

17.1%

EPS

$-0.80

Financial Flow

IONIS PHARMACEUTICALS INC Q3 2025 Financial Summary

IONIS PHARMACEUTICALS INC reported revenue of $156.7M for Q3 2025, with a net profit of $-128.6M (-82.1% margin). Cost of goods sold was $2.3M, operating expenses totaled $314.6M.

Key Financial Metrics

Total Revenue	$156.7M
Net Profit	$-128.6M
Gross Margin	98.5%
Operating Margin	-102.2%
Report Period	Q3 2025

IONIS PHARMACEUTICALS INC Annual Revenue by Year

IONIS PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $705.1M).

Year	Annual Revenue
2024	$705.1M
2023	$787.6M
2022	$587.4M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$324.5M	$119.5M	$225.3M	$133.8M	$226.6M	$131.6M	$452.0M	$156.7M
YoY Growth	113.6%	-8.4%	19.6%	-7.2%	-30.2%	10.1%	100.7%	17.1%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$2.99B	$2.76B	$2.69B	$3.08B	$3.00B	$2.81B	$2.99B	$3.03B
Liabilities	$2.60B	$2.47B	$2.43B	$2.42B	$2.42B	$2.34B	$2.35B	$2.42B
Equity	$386.7M	$296.5M	$263.7M	$662.5M	$588.4M	$475.7M	$631.7M	$618.0M